Sign in to view content

Two years visual acuity and anatomical outcomes of patients with diabetic macular oedema treated with intravitreal aflibercept in a real life setting

Marko Lukic, MD PhD FEBO FASRS

Video
Published 2019

Related

The Functional Burden of Diabetic Retinopathy in the United States – How Ranibizumab May Shift Treatment Paradigms
Jeffrey R Willis, MD/PhD
On Demand Cases, Courses, and Papers
2017
Episode 23: CANTREAT Study. Ranibizumab Monthly vs Treat-and-Extend for wAMD with Dr. Peter Kertes
Keyvan Koushan, MD, FRCSC
Member Podcasts
2019
Five-Year Outcomes After Initial Aflibercept, Bevacizumab, or Ranibizumab Treatment for Diabetic Macular Edema (Protocol T)
Dante Joseph Pieramici, MD
Annual Meeting Talks
2020

Category: Diabetic Retinopathy

See more